

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop C1-26-16 Baltimore, Maryland 21244-1850

CENTER FOR MEDICARE

DATE: September 3, 2021

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section

1876 Cost Plans, Medicare-Medicaid Plans, and PACE plans

FROM: Amy Larrick Chavez-Valdez, Director

Medicare Drug Benefit and C & D Data Group

SUBJECT: CY 2022 September Formulary Enhancement Submission Window

CMS is offering a final CY 2022 formulary enhancement submission window prior to the start of the contract year. While Part D sponsors may enhance their formularies at any time, including prior to the start of the contract year, we are offering this additional window to allow another opportunity for plans to submit formulary enhancements so that the Medicare Plan Finder (MPF) displays accurate and up-to-date formulary information during the Annual Election Period (AEP). Enhancements include the addition of a Part D drug, the movement of a formulary drug to a lower cost-sharing tier, and the removal of utilization management (UM) requirements. Please note that we do not expect sponsors to make significant formulary enhancements during this window, as the formulary that was initially submitted to CMS for review was used to develop the Part D bid. Generic substitutions made in accordance with §423.120(b)(5)(iv) should also be submitted during this window.

The submission window will be open between 12:00 a.m. EDT September 20, 2021 and 5:00 p.m. EDT on September 22, 2021. An updated CY 2022 formulary reference file (FRF) will be available within the CY 2022 HPMS Formulary Submission Module by close of business on September 15, 2021.

If you have any questions regarding this formulary enhancement window, please email PartDFormularies@cms.hhs.gov.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.